期刊
SCIENCE
卷 348, 期 6230, 页码 69-74出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aaa4971
关键词
-
资金
- Worldwide Cancer Research grant [14-0321]
- Dutch Cancer Society grant [NKI 2012-5463]
- Dutch Cancer Society Queen Wilhelmina Award
- Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Cancer Research Grant
- National Cancer Institute [RO1CA04305926]
- Cancer Research Institute
- WWWW Foundation
- Cancer Frontier Fund from The Siteman Cancer Center/Barnes-Jewish Hospital
- Third Rock Ventures
- Kite Pharma
- Jounce Therapeutics
- Worldwide Cancer Research [14-0321] Funding Source: researchfish
The clinical relevance of T cells in the control of a diverse set of human cancers is now beyond doubt. However, the nature of the antigens that allow the immune system to distinguish cancer cells from noncancer cells has long remained obscure. Recent technological innovations have made it possible to dissect the immune response to patient-specific neoantigens that arise as a consequence of tumor-specific mutations, and emerging data suggest that recognition of such neoantigens is a major factor in the activity of clinical immunotherapies. These observations indicate that neoantigen load may form a biomarker in cancer immunotherapy and provide an incentive for the development of novel therapeutic approaches that selectively enhance T cell reactivity against this class of antigens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据